Hospira 4Q10 4Q Revenues: $992.1 million (-6%) 4Q Earnings: $60.6 million (-37%) FY Revenues: $3.9 billion (+1%) FY Earnings: $357.2 million (-12%) Comments: Global Specialty Injectable Pharmaceuticals sales in the quarter were $605.0 million, (+5%). Sales in the Americas were up 4%, Europe, Middle East & Africa sales were up 1%, and Asia Pacific sales were up 10%. For the year, Global Specialty Injectable Pharmaceuticals sales were $2.3 billion, up 13%. Sales in the Americas ...